文献速递消化道肿瘤与早癌消化内镜

Barrett食管进展为肿瘤风险预测模型的开发与验证

Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia.
PubMed 文献 · Gastroenterology · 2017-12-19

基于美国5个中心和荷兰1个中心1985至2014年Barrett食管研究数据库的纵向研究,纳入2697例患者,随访中位5.9年,154例(5.7%)进展为高级别异型增生或食管腺癌,年进展率0.95%。模型基于男性、吸烟、BE长度和基线低级别异型增生评分,c-statistic为0.76(95%CI 0.72-0.80;P<.001),验证队列校准斜率为0.9966(P=.99)。

要点

  • 基于男性、吸烟、BE长度和基线低级别异型增生的评分系统可区分低、中、高风险患者。
  • 模型区分进展为高级别异型增生或食管腺癌的c-statistic为0.76(95%CI 0.72-0.80;P<.001)。
  • 验证队列校准斜率为0.9966(P=.99)。

核心结论

  • 开发了基于男性、吸烟、BE长度和基线低级别异型增生的Barrett食管进展评分系统,可识别低、中、高风险患者,该评分系统可能用于患者管理。

研究设计与样本

  • 美国5个中心和荷兰1个中心的纵向研究,纳入Barrett食管研究数据库中1985至2014年患者,2697例纳入分析(84.1%男性;87.6%白人;平均年龄55.4±20.1岁;平均BMI 27.9±5.5 kg/m2;平均BE长度3.7±3.2 cm)。
  • 70%患者用于推导模型,30%用于验证研究。

主要发现

  • 随访中位5.9年期间,154例患者(5.7%)进展为高级别异型增生或食管腺癌,年进展率0.95%。
  • 男性、吸烟、BE长度和基线确认的低级别异型增生与进展显著相关。
  • 评分识别进展为高级别异型增生或食管腺癌患者的c-statistic为0.76(95%CI 0.72-0.80;P<.001)。
  • 验证队列校准斜率为0.9966(P=.99)。

关键数值与推荐

  • 基于男性、吸烟、BE长度和基线低级别异型增生的评分系统将患者分为低、中、高风险。
  • c-statistic为0.76(95%CI 0.72-0.80;P<.001)。
  • 校准斜率为0.9966(P=.99)。

临床怎么用

  • 作者认为该评分系统可能用于Barrett食管患者的管理。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: A system is needed to determine the risk of patients with Barrett's esophagus for progression to high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC). We developed and validated a model to determine of progression to HGD or EAC in patients with BE, based on demographic data and endoscopic and histologic findings at the time of index endoscopy. METHODS: We performed a longitudinal study of patients with BE at 5 centers in United States and 1 center in Netherlands enrolled in the Barrett's Esophagus Study database from 1985 through 2014. Patients were excluded from the analysis if they had less than 1 year of follow-up, were diagnosed with HGD or EAC within the past year, were missing baseline histologic data, or had no intestinal metaplasia. Seventy percent of the patients were used to derive the model and 30% were used for the validation study. The primary outcome was development of HGD or EAC during the follow-up period (median, 5.9 years). Survival analysis was performed using the Kaplan-Meier method. We assigned a specific number of points to each BE risk factor, and point totals (scores) were used to create categories of low, intermediate, and high risk. We used Cox regression to compute hazard ratios and 95% confidence intervals to determine associations between risk of progression and scores. RESULTS: Of 4584 patients in the database, 2697 were included in our analysis (84.1% men; 87.6% Caucasian; mean age, 55.4 ± 20.1 years; mean body mass index, 27.9 ± 5.5 kg/m2; mean length of BE, 3.7 ± 3.2 cm). During the follow-up period, 154 patients (5.7%) developed HGD or EAC, with an annual rate of progression of 0.95%. Male sex, smoking, length of BE, and baseline-confirmed low-grade dysplasia were significantly associated with progression. Scores assigned identified patients with BE that progressed to HGD or EAC with a c-statistic of 0.76 (95% confidence interval, 0.72-0.80; P < .001). The calibration slope was 0.9966 (P = .99), determined from the validation cohort. CONCLUSIONS: We developed a scoring system (Progression in Barrett's Esophagus score) based on male sex, smoking, length of BE, and baseline low-grade dysplasia that identified patients with BE at low, intermediate, and high risk for HGD or EAC. This scoring system might be used in management of patients.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Parasa S, Vennalaganti S, Gaddam S, et al. Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia. Gastroenterology. 2017. PMID: 29273452. doi:10.1053/j.gastro.2017.12.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。